Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05210582
Other study ID # CUV104
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 11, 2022
Est. completion date August 2023

Study information

Verified date February 2023
Source Clinuvel Pharmaceuticals Limited
Contact Head of Clinical Operations
Phone +441372860765
Email mail@clinuvel.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.


Recruitment information / eligibility

Status Recruiting
Enrollment 6
Est. completion date August 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male and female patients with a confirmed diagnosis of vitiligo on the face and with T-VASI range 0.5-50% - Stable face vitiligo with F-VASI of at least 0.1% - Stable or slowly progressive vitiligo over a 3-month period - Fitzpatrick skin types IV-VI - Treatment with narrowband (NB)-UVB light 2-3 times per week during the last four weeks preceding the first implant for priming Exclusion Criteria: - Patients with segmental vitiligo - Fitzpatrick skin types I-III - Treatment with NB-UVB phototherapy in the last three months prior to phototherapy, excluding the sessions for priming in the four weeks prior to treatment. A 3-month washout period from phototherapy is necessary prior to priming. - Previous topical treatment for vitiligo - Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant - History of melanoma or lentigo maligna - Any current skin disease that may interfere with the study evaluation - Presence of severe hepatic disease or hepatic impairment - Renal impairment - History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation - Female who is pregnant or lactating - Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter - Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above - Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit - Use of any other prior and concomitant therapy which may interfere with the objective of the study - Subjects assessed as not suitable for the study in the opinion of the Investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Afamelanotide
Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.

Locations

Country Name City State
United States CLINUVEL Investigational site Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Clinuvel, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions Measured using Vitiligo Area Scoring Index (VASI). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100) From Baseline to Day 84
Secondary Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on body surface area Proportion of participants achieving VASI25 on body surface area (excluding hands and feet). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100). From Baseline to Day 84
Secondary Percentage change in pigmentation on body surface area measured by the VASI scoring system Percentage change in pigmentation on body surface area (excluding hands and feet) measured by VASI scoring system. A decrease in VASI indicates a reduction of the body surface area affected by vitiligo (possible range 1-100) From Baseline to Day 84
Secondary Percentage change in pigmentation on facial surface area measured by the VASI scoring system A decreased VASI indicates a reduction in the faces' degree of depigmentation (possible range 1-100) From Baseline to Day 168
Secondary Change in Perception of Vitiligo Severity using a vitiligo validated specific tool (A) The higher the score, the more severe the disease From Baseline to Day 168
Secondary Change in Noticeability of Vitiligo using a vitiligo validated specific tool (B) Higher the value means lower noticeability From Baseline to Day 168
Secondary Change in Quality of life using a vitiligo specific tool (C) Higher value means a lower quality of life From Baseline to Day 168
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05298033 - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo Phase 2
Recruiting NCT05872477 - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas Phase 2
Not yet recruiting NCT05927272 - Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions N/A
Terminated NCT04374435 - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo N/A
Completed NCT04103060 - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Phase 2
Terminated NCT04271501 - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions N/A
Completed NCT04530344 - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Phase 3
Not yet recruiting NCT05008887 - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo Phase 4
Terminated NCT02191748 - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Phase 2/Phase 3
Terminated NCT01262547 - A New Micrografting Technique for Vitiligo Phase 2
Completed NCT01382589 - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Phase 2
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Completed NCT04547998 - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions N/A
Not yet recruiting NCT04039451 - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting NCT03611348 - Microneedling and Latanoprost in Acrofacial Vitiligo Phase 2/Phase 3
Recruiting NCT03199664 - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Phase 4
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT03249064 - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo N/A
Recruiting NCT05635266 - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives